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Abstract 
Introduction: Despite vancomycin being in use for over half-a-century, it is still not dosed or 
monitored appropriately in many centers around the world.  The objective of this study was to 
determine the effectiveness of a multifaceted intervention to implement a vancomycin dosing and 
monitoring guideline across multiple medical and surgical units over time. 
Methods: This was an observational before-and-after interventional cohort study. The pre-
intervention period was August to December 2010-2011 and the post-intervention period was 
September to November 2012-2014. The implementation strategy comprised: face-to-face 
education, online continuing medical education, dissemination of pocket guideline and email 
reminder. Outcome measures included: appropriate prescribing of loading and maintenance doses, 
therapeutic drug monitoring, time to attain target range and nephrotoxicity. 
Results: Post-implementation prescribing of loading doses increased (10.4% to 43.6%, P=<0.001), 
guideline adherent first maintenance dose (44% to 68.4% P=0.04), correct dose adjustment from 
(53.1% to 72.2%, P=0.009). Beneficial effects pre and post-implementation were observed for 
adherent timing of initial concentration (43.2% to 51.9%, P=0.01), concentrations in target range 
(32.6% to 44.1%, P=0.001), time to target range (median 6 to 4 days, P=<0.001), potentially 
nephrotoxic concentrations (30.7% to 20.9%, P=<0.001) and nephrotoxicity (10.4% to 6.8%, 
P=<0.001). 
Conclusions: A multifaceted intervention to implement a vancomycin dosing and monitoring 
guideline significantly improved prescribing, monitoring, pharmacokinetic and safety outcomes for 
patients treated with vancomycin over an extended period. However, increased guideline adoption 
by clinicians is required to maximize and prolong the utility of this important agent. 
 





Vancomycin has been in use for over half a century however we still have difficulty prescribing and 
monitoring this agent [1-2]. Practice recommendations have changed over time [3].To address these 
changes in practice and promote contemporary clinical guidance, a number of a professional 
societies from various nations, notably the United States, Japan and recently, China, have published 
vancomycin guidelines in the medical literature [4-6]. These national guidelines are in addition to the 
plethora of institutional vancomycin guidelines that been described in a recent systematic review 
[7].  Significant financial and human resources are invested into the development of transparent 
evidence-based clinical practice guidelines, however there is very limited information supporting 
these documents reflecting which implementation strategies best promote the guideline adoption.  
 
To address guideline implementation, organisations involved with knowledge translation and 
guideline development including the National Institute for Health and Clinical Excellence (NICE), UK, 
the Scottish Intercollegiate Guideline Network (SIGN), the Australian National Health and Medical 
Research Council (NHMRC), the United States Institute of Medicine (IOM) and Guidelines 
International Network (G-I-N) provide general advice on guideline implementation [8-12]. This is 
important as there are numerous accounts in the literature of poor adoption of guidelines by 
clinicians [13-16]. Most of the peak organisations advocate for multifaceted interventions when 
implementing guidelines. 1 Commonly recommended interventions by these organisations are: 
educational sessions [17], academic detailing [18-20], continuing medical education (CME) [21-22], 
provision of printed educational material [23], use of opinion leaders to endorse guidelines [24], and 
engaging target populations who will use the guideline [25]. However, the magnitude of effect from 
                                                          
Abbreviations: CME, continuing medical education; FMC, Flinders Medical Center; GIN, Guideline International 
Network; ICCU, Intensive and critical care unit; IOM, Institute of Medicine; JMO, junior medical officer; MRSA, 
methicillin-resistant Staphylococcus aureus; NHMRC, National Health and Medical Council; NICE, National 
Institute for Clinical Excellence, SIGN, Scottish Intercollegiate Guideline Network; VRE, vancomycin-resistant 
Enterococcus. 
 
these interventions varies considerably and the impact these interventions have specifically when 
employed to implement vancomycin guidelines is unknown.  
 
In a pilot study we implemented a vancomycin dosing and monitoring guideline, we elected to use 
interventions involving face-to-face education and the provision of a pocket guideline as these had 
limited cost implications. Despite low statistical power, the pilot produce favourable results, 
increasing prescribing of loading doses from 5-65% (P= ≤ 0.001), adherent first maintenance dosages 
from 43-75% (P=0.04), more concentrations in target range from 27%-43.8% (P=0.04), and non-
significant reductions in potentially toxic concentrations , reduced nephrotoxicity and a trend to 
more patients attaining target ranger sooner [26]. However, as that pilot was conducted in a single 
surgical unit, it was unclear if the results of the intervention would be reproducible and sustainable.   
Thus the objectives of the current study were to determine the effectiveness of a multifaceted 




Patients and methods 
Study setting and design 
The study was an observational cohort before-and-after interventional design. The study was 
conducted at Flinders Medical Centre (FMC), a 580 bed government university teaching hospital in 
Adelaide, Australia. The interventional cohort was all adult patients treated with vancomycin during 
the months, September to November over three years 2012-2014. This interval is defined as the 
follow-up period. A pre-implementation comparator group included all patients treated with 
vancomycin during the months August to December over two years 2010-2011. Ethical approval for 
the study granted by the Southern Adelaide Clinical Human Research Ethics Committee, Australia 
(approval number 123.12). 
 
Patients  
Admitted patients ≥18 years receiving vancomycin who had ≥1 vancomycin concentration result 
were included in the study. Patients were identified from the daily therapeutic drug monitoring 
report generated by the biochemistry department. Patients were excluded if they commenced 
treatment in the intensive and critical care unit (ICCU), receiving hemo- or peritoneal dialysis, this 
was due to both units having dedicated vancomycin dosing protocols.  
 
Serum creatinine measurement and creatinine clearance calculation 
Serum creatinine (SCr) concentrations were measured using Roche (Basel, Switzerland) C702 
enzymatic method. Calculation of creatinine clearance (CrCl) was performed using the Cockcroft-
Gault equation, 






The vancomycin dosing and monitoring guideline for adults used in this study was based on a 
guideline developed for a single unit pilot study in our institution [26], later used in a broader proof 
of concept study across medical and surgical units [28]. The guideline largely reflected the North 
American consensus recommendations adapted with Australian Therapeutic Guidelines content on 
vancomycin [29-30]. The current study guideline was endorsed with input from institutional leaders 
in infectious diseases, clinical pharmacology and pharmacy, refined in early 2012 and uploaded to 
the institutions intranet in August 2012. Key prescribing features were: a loading dose of 25mg/kg at 
discretion of prescriber and maintenance dosing determined by CrCl (>90mL/min 1.5g 12-hourly; 60-
90mL/min 1g 12-hourly; 20-59mL/min 1g 24-hourly; <20mL/min 1 g every 2-7 days with vancomycin 
TDM 48-hourly). Key monitoring features were: timing of initial trough blood sample for 
concentration measurement was determined by CrCl (>60mL/min required blood to be taken prior 
to the fourth dose; 20-59mL/min before the third dose and <20mL every 48-hourly until target (15-
20mg/L) attainment) (Supplementary file 1). In the pre-implementation period there was no 
institutional guidance on vancomycin dosing and monitoring except for a comment on pathology 
result record or electronic report of a target range 15-20mg/L. This comment remained in effect for 
the follow-up period. 
 
Target audience 
The principal target audience of the implementation strategy was junior medical officers 
(postgraduate years 1 and 2) as they perform the majority of prescribing and pathology test ordering 
in our and many other institutions [31]. However, all medical, pharmacy and nursing staff were 




There were four components to the multifaceted intervention to support the release of the 
guideline:  1) educational session, 2) an online continuing education module on vancomycin with 
knowledge assessment, 3) dissemination of printed material and 4) email reminder alert.  
 
Education session: Learning objectives for the session were for JMOs to become familiar with the 
guideline and be able to dose and monitor vancomycin effectively for patients. Three identical 60-
minute face-to-face educational sessions were provided to JMOs periodically through the year. The 
session was provided in a dedicated university teaching room in the hospital, located in close 
proximity to patient wards, facilitating ease of attendance. Attendance was voluntary and no 
incentives were offered other than lunch. The session contained information on pharmacology and 
indications, local audit data on vancomycin prescribing and monitoring, and MRSA prevalence. Issues 
of reduced susceptibility to vancomycin and minimising the development of resistance, limiting 
nephrotoxicity and the pharmacoeconomics of comparative agents was presented. Importantly the 
session included a clinical vignette with practical advice on how to dose and monitor vancomycin. 
The sessions were delivered by CJP a pharmacist educator who is an experienced facilitator, has 
expertise in clinical education, pharmacotherapy of infectious diseases and therapeutic drug 
monitoring. Fidelity of the content and delivery of the educational sessions was assured by CJP 
providing all sessions over 2012-14. One variance to this was the addition of the Infectious Diseases 
registrar as a co-presented at sessions in 2012. 
 
Online continuing education: was provided to JMOs in the latter half of the hospital training year 
over 2012-14. The CME document was formally emailed via the Trainee Medical Officer Unit. The 
CME contained background information on vancomycin and how to dose and monitor vancomycin 
and a clinical vignette and questions. The details of this intervention have been provided in detail 
elsewhere [32].  An electronic copy of the guideline was also provided with the CME.  
 
 
Dissemination of printed material (pocket guideline): A small pocket size version of the guideline 
(6cm x 10cm) compatible for attaching to hospital identification badges was provided to all JMOs.  
The pocket guideline was disseminated at all vancomycin educational sessions and from the Trainee 
Medical Officer Unit for those unable to attend. The pocket guideline was also provided to all 
pharmacy staff in their clinical induction. 
 
Email alert: The Director of Medical Services sent a reminder email to all medical staff soon after the 
guideline was uploaded to the intranet (August 2012). The email advised staff where to locate the 
guideline and requested staff adherence to the guideline.  
 
Outcome measures / process measure 
Outcomes measures for vancomycin prescribing: loading doses, first maintenance dose adherent to 
guideline and appropriate dosage adjustment in response to concentrations outside target range, 
i.e. if a vancomycin concentration returned below target, was the next dose increased? Conversely, 
if the vancomycin concentration result was above target range, was the next dose reduced? 
Monitoring outcomes were proportion of vancomycin initial concentrations  taken at steady-state 
concentration, proportion of appropriate pre-dose trough concentrations  attainment of trough 
concentrations  in therapeutic range (15-20mg/L) and time to achieve therapeutic range, and 
potentially nephrotoxic trough concentrations (>20mg/L). Nephrotoxicity was included as a safety 
outcome, defined as a rise in serum creatinine of ≥50% or 50mg/dL from baseline on two or more 
consecutive days of vancomycin therapy  in the absence of an alternative explanation [33]. A process 
measure was the frequency of intranet access of the vancomycin guideline.  
 
Power calculation and statistical analysis 
The study was powered to detect similar differences in the proportion of patients within target 
range between pre and post intervention periods to those observed in the pilot study where we 
 
observed a 16.9% increase from 26.9% to 43.8% [26]. Assuming a similar proportion of 26.9% at 
baseline, a sample size of 125 subjects in both the pre and post intervention groups (n=250 total) 
would be required to have 80% power to detect the same increase at a two-sided Type 1 error rate 
of P<0.05. The study had more than 90% power to detect a reduction in the median time to target 
range from 5 days to 3 days, similar to the changes observed in a pilot study. Differences in clinical 
characteristics of subjects between the pre and post-implementation phases was assessed using an 
independent t-test for normally distributed continuous variables and a Mann-Whitney U test for 
non-normally distributed data. Differences in proportions and categorical variables were assessed 
using 2-sample tests of proportions and chi-squared tests of association respectively. Differences in 
the time to reach therapeutic range since commencing vancomycin between subjects was assessed 
using Kaplan-Meier plots and log-rank statistics. Subjects that did not reach the therapeutic range 
were censored at the end of their follow-up period. All analysis was performed using Stata version 




Patient characteristics  
There were 258 subjects in the study. The interventional cohort consisted of 133 patients receiving 
vancomycin treatment in hospital and the pre-implementation cohort included 125 patients. Patient 
characteristics between the two groups were similar with exceptions in the pre-implementation 
group which had a longer median stay, more patients coming from residential aged care facilities, 
higher vancomycin-resistant Enterococcus (VRE) colonisation and more patients managed by surgical 
teams. More patients in the post-implementation group had comorbidity with malignancy and 
congestive heart failure (Table 1). There were no differences between groups for infection site or 
microbiological data (Table 2).  
 
Outcomes measures 
In the post-implementation group, there were significant increases in guideline-adherent prescribing 
of loading and first maintenance doses.  The median time with interquartile range (IQR) of the first 
concentration attained in therapeutic target range reduced significantly from 6 (4-9) to 4 (3-6) days 
in the post-implementation group (P= <0.001) (Table 3). The time taken to reach target for all 
patients that had a measured concentration was significantly reduced from 25 to 13 days post-
implementation (P= <0.001) (Fig 1). The overall duration of vancomycin therapy decreased from a 
median of 9 days (IQR 5-13) to 5 days (4-9) for those in the post implementation group (P= <0.001). 
The proportion of initial concentrations drawn at the correct times (i.e. vancomycin reached steady-
state concentration in the serum) improved from 43.2% to 51.9% in the post-implementation group 
(P=0.01). A significantly greater number of patients post-implementation attained target trough  
range (15-20mg/L) 32.6% vs 44.1% (P= <0.001), and fewer reached potentially nephrotoxic trough 
concentrations  (>20mg/L) with a decrease from 30.7% to 20.9% post-implementation (P= <0.001). 
The safety outcome of nephrotoxicity post-implementation was also significantly decreased from 
10.4% to 6.8% (P= <0.001) (Table 3).  
 
A sub-analysis was performed on those patients that attained their initial concentration within 
target range (n=9 pre-implementation and n=32 post-implementation) and whether they were 
prescribed recommended loading and initial maintenance doses. Pre-implementation only 3 patients 
of the 9 (3/9) 33.3% received recommended prescribing compared to 12/32 (37.5%) post-
implementation (P=0.82). A sub-analysis was also performed on those patients that acquired 
nephrotoxicity (n=13 pre-implementation and n=9 post-implementation) and whether they received 
an appropriate initial maintenance dose. Pre-implementation 6 patients (9/13) 43.2% were 
prescribed appropriate initial maintenance doses compared to 5/9 (55.5%) post-implementation 
(P=0.66).  
  
The effect changes observed for prescribing, monitoring and duration of treatment for the post 
implementation group were largely sustained or improved when examined by individual year for 
2012, 2013 and 2014 (Table 4). A notable variant was nephrotoxicity, which had a lower incidence in 




The vancomycin guideline accessed from the hospital intranet was recorded monthly from upload in 
August 2012 until December 2014. The guideline was consistently accessed with a mean and 




In this study we demonstrated that a multifaceted intervention improved guideline-adherent 
vancomycin prescribing, resulting in hospital inpatients more rapidly attaining target concentrations, 
which have been associated with improved clinical outcomes and reduced risk of nephrotoxicity [34-
35]. The findings observed in the current study were generally consistent with our pilot [26], and we 
showed meaningful reductions in the duration of vancomycin treatment and nephrotoxicity. We 
have been explicit in reporting our methodology and study design which has recently been identified 
as a priority when seeking to change behaviour regarding the use of antibiotics in hospitals [36], and 
specifically for guideline dissemination and implementation [37]. Furthermore, we have quantified 
the effect of our multifaceted intervention, which comprises commonly recommended strategies, 
specifically for the purpose of implementing a vancomycin guideline.  
 
A major review on the effectiveness of guideline dissemination and implementation strategies found 
that the majority of multifaceted interventions had a median absolute improvement in care of 14.1% 
for reminders and 8.1% for dissemination of educational material [38]. Our study used education, 
dissemination of educational material and reminder email. We observed more than a four-fold 
increase in prescribing of loading doses, a fifty-percent rise in appropriate maintenance dosing and a 
thirty-percent rise in attainment of target range. We used face-to-face educational sessions as a key 
pillar of our implementation strategy. A Cochrane review on educational meetings and workshops in 
healthcare found from 30 trials, the median (IQR) difference in compliance for practice measures 
was a modest 6% (1.8% to 15.9%) where education was a component of an intervention compared 
to no intervention. Mixed interactive and didactic educational meetings had a difference median of 
13.6%. The median (IQR) difference observed on patient outcomes was only 3% (0.1% to 4.0%) [17]. 
A Cochrane review on providing educational material to physicians when compared to no 
intervention showed a median (IQR) effect increase for categorical measures of 2% (0% to 11%) and 
a mean (range) effect increase of 13% (16% to 36%) when followed-up to 6 and 9 months 
 
respectively [39]. We provided an electronic CME on vancomycin and a printed pocket guideline to 
junior doctors. The magnitude of effect for each of our interventions is unclear, however the 
changes in our outcome measures are considerable in excess of those reported above. 
 
Although our study demonstrated significant improvements for most outcomes measures, that fact 
remains that less than half of all vancomycin concentrations were within the target range and there 
is still considerable room for improvement. This study focused on building prescribers knowledge of 
the clinical use vancomycin, and awareness of consequences to patients if vancomycin is not 
prescribed appropriately. The reasons why some doctors did not use the guideline are not clear. It 
has been reported in the literature that some doctors may lack agreement with guidelines, have a 
distrain for rigid medicine and guidelines may be seen as encroaching on professional autonomy and 
a disbelief that following the guideline will achieve the desired outcomes [15]. Furthermore, 
insufficient time to use guidelines, lack of peer or superiors support, have also been identified as 
factors influencing adherence to guidelines [16].  It is important these attitudinal factors are given 
greater consideration when designing implementation strategies to improve the ongoing use of 
vancomycin. 
 
A strength of this study was that the implementation strategy was executed consistently and with 
fidelity, providing confidence in the results. The sustained effect observed over three years provides 
further confidence as many other studies measuring the effect of vancomycin guidelines are much 
shorter in duration.  The finding from this study are corroborated with the process measure of 
intranet access of the guidelines over the same time period demonstrating a consistency of 
electronic access to the guideline. Considerable rigour has gone into reporting the details of our 
interventions, in particular the educational component to enable others to reproduce our work. We 
assessed our description of the educational component of the intervention against a recently 
published guidance for the reporting of evidence-based educational interventions in health and 
 
found 13 of the 17 criteria were met [40]. Our study had some limitations. The study was conducted 
at a single centre and data was collected retrospectively.  There were some significant differences in 
baseline characteristics that may have impacted on the results. Notably pre-implementation there 
were more patients from residential aged care facilities with higher rates of VRE colonization, 
suggesting these patients may have been more complex and frail. This in turn may have made 
attainment of appropriate vancomycin target concentrations more difficult. However, post-
implementation more patients having malignancy and congestive heart failure may have also 
adversely impacted monitoring outcomes. Cancer has been reported to alter clearance of 
vancomycin [41], and congestive heart failure is known to decrease vancomycin clearance [42]. 
Potentially both these factors may have resulted in more patients failing to attain target 
concentration. Furthermore the longer median duration of admission post-implementation can be 
attributable to an unusually complex patient with a surgical site infection that was admitted for 107 
days. 
 
Whilst provider or facilitator fatigue did not feature in this study, it is possible that this may be a 
variable which could bias results. Future elements to add to this multifaceted intervention, could be 
the incorporation of guideline content into electronic prescribing as has been suggested by the IOM 
[8].  In recent times much has been made of pharmacokinetic/pharmacodynamic monitoring of 
vancomycin using area-under-the-curve (AUC) / minimum inhibitory concentration (MIC) originally 
derived by Moise et al. [43], and MRSA isolates with elevated MIC [44]. We elected not to 
promulgate AUC/MIC monitoring in our guideline nor sought to record it as an outcome measure, as 
a recently published study on MRSA clinical isolates from our institution found all MRSA isolates had 
an MIC ≤1mg/L when determined by broth microdilution [45]. 
 
These data confirm the efficacy over time of a systematic implementation strategy to improve the 
dosing and monitoring of vancomycin which is likely to be similarly applicable to other antimicrobial 
 
agents and as well as to improving prescribing more broadly. Our findings provide some guidance to 
those tasked with allocation of resources for local guideline implementation, enabling clinicians to 
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Figure and tables legend 
Table 1: Demographics and clinical characteristics of patients 
Table 2: Infection site and microbiological data 
Table 3: Outcome measurements of vancomycin prescribing and monitoring 
Table 4: Temporal outcome measurements of vancomycin prescribing and monitoring 















n =133 (%)* 
 
P1 
Characteristic    
Age, years mean (SD) 64.4 (19.2) 63.7 (19.5) 0.77 
Male sex 74 (59.2) 79 (59.4) 0.54 
Residence in RACF 64 (51.2) 26 (19.5) <0.001 
Prior admission to hospital  
≤12 months 
95 (76%) 89 (66.9) 0.07 
Prior colonisation with MRO  
In ≤12 months 
   MRSA  













CrCL, mL/min mean (SD) 102.7 (60.8) 93.5 (52.5) 0.19 
Weight, kg mean (SD) 81.2 (21.9) 78.1 (22.7) 0.27 
Comorbidities  
   Diabetes 
   Malignancy 
   Valvular disease 
















Medication / allergic status 
   Aminoglycoside 











   Medical 










Days of admission; 
median (IQR) 
10 (3-17) 13 (7.8-24.3) 0.02 
*Unless otherwise stated: CrCL, creatinine clearance; IQR, interquartile range; RACF, residential aged 
care facility; MRO, multi-resistant organism; MRSA, methicillin-resistant Staphylococcus aureus; SD, 
standard deviation; VRE, vancomycin-resistant Enterococcus 




Table 2  













   Bacteraemia/ cardiac 
   Synovial/prosthetic  
   CNS/cranial  
   Skin & soft tissue infection 
   Osteomyelitis 
   Respiratory 
   GI/abdominal infection 





























   MRSA 
   Enterococcus spp 
   CoNS 
   Staphylococcus epidermidis 
   MSSA 
   Other 
   No growth detected  




























*Unless otherwise stated: CNS, central nervous system; GI, gastrointestinal; Spp, bacterial species; MRSA, methicillin-
resistant Staphylococcus aureus; CoNS, coagulate negative Staphylococcus aureus; MSSA, methicillin-sensitive 
Staphylococcus aureus; † Note some patients had infection with more than one organism 




Table 3  
Outcomes measurements of vancomycin prescribing and monitoring  













n =133 (%)* 
 
P1 
Prescribing    
Loading dose prescribed 12 (10.4) 58 (43.6) <0.001 
First maintenance dose adherent 55 (44) 91 (68.4) 0.04 
First dose adjustment correct≠ 51/96 (53.1) 60/82 (72.2) 0.009 
Days of vanco treatment; 
Median (IQR) 
9 (5-13) 5 (4-9) <0.001 
Monitoring    
Total number of conc.  per 
treatment days 
506/977= 0.52 408/1061 = 0.38 0.12 
Css. adherent timing of initial 
conc.  
54 (43.2) 69 (51.9) 0.01 
Days until first conc. in target; 
median (IQR) 
6 (4-9) 4 (3-6) <0.001 
Potentially subtherapeutic conc. 
<10mg/L 
48 (15) 34 (12.1) 0.71 
Conc. in target range  
15-20mg/L 
104 (32.6) 124 (44.1) 0.001 
Potentially nephrotoxic 
conc.>20mg/L 
98 (30.7) 59 (20.9) <0.001 
Nephrotoxicity 13 (10.4) 9 (6.8) <0.001 
*Unless otherwise stated: Conc, concentration; Css, concentration steady-state achieved; IQR, interquartile range; 
vanco, vancomycin; 
≠
first dose adjustment correct where vancomycin continuing and not in target range   
1Using t-test for normally distributed data, Mann-Whitney U test for non-normally distributed data, 





Table 4  









2012                       2013                          2014 
n=39                        n=48                         n=46 
 
Prescribing     
Loading dose 
prescribed 
12 (10.4) 10 (25.6) 28 (58.3) 20 (43.5) 
First maintenance 
dose adherent 










Days of vanco 
treatment; 
Median (IQR) 
9 (5-13) 4 (4-11.5) 6 (4-10.8) 5 (3-7) 
Monitoring     
Total number of 
conc. per 
treatment days 
506/977= 0.52 132/345=0.38 155/411=0.38  121/305=0.40 
Adherent pre-dose 
trough conc. 
319/506 (63) 98/132 (74.2) 96/155 (61.9) 87/121 (71.9) 
Css adherent 
timing of initial 
conc. 
54 (43.2) 21 (53.8) 25 (50.1) 23 (50) 
Days until first 
conc. in target; 
median (IQR) 




48 (15) 16 (16.3) 8 (8.3) 10 (11.5) 
Conc. in target 
range  
15-20mg/L 




98 (30.7) 18 (18.4) 23 (24) 18 (20.7) 
Nephrotoxicity  13 (10.4) 3 (7.7) 1 (2.1) 5 (10.9) 
*n, (%) Unless otherwise stated: Conc, concentration; Css, concentration steady-state; IQR, interquartile range; vanco; 
vancomycin; 
≠
first dose adjustment correct where vancomycin continuing and not in target range  
 
